Connect with us

Hi, what are you looking for?

Tech & Science

Atopic dermatitis treatment sees promising future with new drug approvals

As these treatments enter the market, they underscore the increasing focus on enhancing care for those affected by this widespread condition.

Spa treatment. Image by IQP - CC BY-SA 3.0,
Spa treatment. Image by IQP - CC BY-SA 3.0,

Atopic dermatitis (AD) is experiencing a shift in treatment management with recent drug approvals that address unmet needs. The introduction of novel therapies, such as Dermavant’s VTAMA (tapinarof) (Japan) and Arcutis’s ZORYVE (roflumilast) (US), with new mechanisms of action, offers hope for improved patient outcomes.

As these treatments enter the market, they underscore the increasing focus on enhancing care for those affected by this widespread condition.

GlobalData’s recent report “Atopic Dermatitis Epidemiology Analysis and Forecast,” reveals that the number of the diagnosed prevalent cases of atopic dermatitis (AD) across the seven major markets is expected to increase at an annual growth rate of more than 0.02 percent between 2020 and 2030.

Filippos Maniatis, Healthcare Analyst at GlobalData explains: “It is an exciting time for the treatment landscape of AD as multiple therapies are coming closer to approval. VTAMA (tapinarof) and ZORYVE (roflumilast) in Japan and the US, respectively, bring further excitement to the wider community for what the future holds in the treatment landscape of AD.”

The severity of disease helps physicians to decide on the treatment that will be followed for AD patients. The basic treatment aims to help with avoiding triggers through bath oils and emollients, whereas in mild cases (EASI score), emollients are used to restore the skin barrier.

The current therapies for AD encompass topical and systemic treatments, including inhibitors that target Janus kinases (JAK), phosphodiesterases, calcineurin, and interleukins (ILs), as well as aryl hydrocarbon receptor agonist (AhR) modulators and immunosuppressants.

 Vtama and Zoryve possess interesting mechanisms of action (MoAs). Vtama is an AhR agonist and presents a novel mechanism for AD, as no other marketed therapies employ it. Zoryve is a phosphodiesterase-4 (PDE4) inhibitor, and this MoA has been previously seen in Pfizer’s Eucrisa (crisaborole).

Following recent approvals, the AD community is looking forward to promising outcomes from both therapies upon their use in AD patients. The AD space is very dynamic, with multiple pipeline agents currently in clinical trials. The addition of Vtama and Zoryve is promising and may provide an additional benefit to AD patients as their unmet needs related to the lack of effective AD therapies are further addressed. Maniatis adds: “AD is currently experiencing increased attention by pharma companies as there are still unmet needs that need to be addressed. Clinical trials are evaluating new mechanisms of action against AD, such as BTLA and OX40 inhibitors which have shown promising results as potential therapies for AD in Phase 2 and Phase 3 trials, denoting the opportunity for further research around potential AD treatments.”

Avatar photo
Written By

Dr. Tim Sandle is Digital Journal's Editor-at-Large for science news. Tim specializes in science, technology, environmental, business, and health journalism. He is additionally a practising microbiologist; and an author. He is also interested in history, politics and current affairs.

You may also like:

Entertainment

Actor and filmmaker Tyler Gallant chatted about his future projects, the digital age, and his career in the entertainment business.

Entertainment

On Sunday, February 9th, Grammy-nominated singer and actor Brent Comer (of the Tony award-winning Broadway musical "The Outsiders") headlined 54 Below in New York...

Tech & Science

Political and tech industry leaders were set to descend on Paris Monday for a two-day summit on artificial intelligence.

Business

Equities were mixed in Asia on Monday after Trump ramped up his trade war by announcing huge tariffs on steel and aluminium imports.